Chen Ru, Brentnall Teresa A, Pan Sheng, Cooke Kelly, Moyes Kara White, Lane Zhaoli, Crispin David A, Goodlett David R, Aebersold Ruedi, Bronner Mary P
Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, Washington 98195, USA.
Mol Cell Proteomics. 2007 Aug;6(8):1331-42. doi: 10.1074/mcp.M700072-MCP200. Epub 2007 May 12.
The effective treatment of pancreatic cancer relies on the diagnosis of the disease at an early stage, a difficult challenge. One major obstacle in the development of diagnostic biomarkers of early pancreatic cancer has been the dual expression of potential biomarkers in both chronic pancreatitis and cancer. To better understand the limitations of potential protein biomarkers, we used ICAT technology and tandem mass spectrometry-based proteomics to systematically study protein expression in chronic pancreatitis. Among the 116 differentially expressed proteins identified in chronic pancreatitis, most biological processes were responses to wounding and inflammation, a finding consistent with the underlining inflammation and tissue repair associated with chronic pancreatitis. Furthermore 40% of the differentially expressed proteins identified in chronic pancreatitis have been implicated previously in pancreatic cancer, suggesting some commonality in protein expression between these two diseases. Biological network analysis further identified c-MYC as a common prominent regulatory protein in pancreatic cancer and chronic pancreatitis. Lastly five proteins were selected for validation by Western blot and immunohistochemistry. Annexin A2 and insulin-like growth factor-binding protein 2 were overexpressed in cancer but not in chronic pancreatitis, making them promising biomarker candidates for pancreatic cancer. In addition, our study validated that cathepsin D, integrin beta1, and plasminogen were overexpressed in both pancreatic cancer and chronic pancreatitis. The positive involvement of these proteins in chronic pancreatitis and pancreatic cancer will potentially lower the specificity of these proteins as biomarker candidates for pancreatic cancer. Altogether our study provides some insights into the molecular events in chronic pancreatitis that may lead to diverse strategies for diagnosis and treatment of these diseases.
胰腺癌的有效治疗依赖于疾病的早期诊断,这是一项艰巨的挑战。早期胰腺癌诊断生物标志物开发中的一个主要障碍是潜在生物标志物在慢性胰腺炎和癌症中均有表达。为了更好地理解潜在蛋白质生物标志物的局限性,我们使用同位素标记相对和绝对定量(ICAT)技术以及基于串联质谱的蛋白质组学方法,系统地研究了慢性胰腺炎中的蛋白质表达。在慢性胰腺炎中鉴定出的116种差异表达蛋白中,大多数生物学过程是对创伤和炎症的反应,这一发现与慢性胰腺炎相关的潜在炎症和组织修复一致。此外,在慢性胰腺炎中鉴定出的差异表达蛋白中有40%先前已被认为与胰腺癌有关,这表明这两种疾病在蛋白质表达上存在一些共性。生物网络分析进一步确定c-MYC是胰腺癌和慢性胰腺炎中共同的突出调节蛋白。最后选择了5种蛋白通过蛋白质免疫印迹法和免疫组织化学法进行验证。膜联蛋白A2和胰岛素样生长因子结合蛋白2在癌症中过表达,但在慢性胰腺炎中未过表达,这使其成为胰腺癌有前景的生物标志物候选物。此外,我们的研究证实组织蛋白酶D、整合素β1和纤溶酶原在胰腺癌和慢性胰腺炎中均过表达。这些蛋白在慢性胰腺炎和胰腺癌中的阳性参与可能会降低这些蛋白作为胰腺癌生物标志物候选物的特异性。总之,我们的研究为慢性胰腺炎中的分子事件提供了一些见解,这可能会带来针对这些疾病的诊断和治疗的多种策略。